Armistice Capital LLC Boosts Stake in Genprex, Inc. (NASDAQ:GNPX)

Armistice Capital LLC grew its stake in Genprex, Inc. (NASDAQ:GNPX) by 122.7% during the second quarter, HoldingsChannel reports. The fund owned 218,000 shares of the company’s stock after acquiring an additional 120,132 shares during the quarter. Armistice Capital LLC owned about 0.10% of Genprex worth $411,000 as of its most recent SEC filing.

Genprex Stock Performance

Shares of NASDAQ GNPX opened at $0.35 on Friday. Genprex, Inc. has a 1-year low of $0.28 and a 1-year high of $16.94. The business has a fifty day moving average price of $0.94 and a 200 day moving average price of $1.97.

Genprex (NASDAQ:GNPX) last announced its earnings results on Friday, August 9th. The company reported ($3.00) EPS for the quarter, missing analysts’ consensus estimates of ($2.30) by ($0.70). On average, research analysts predict that Genprex, Inc. will post -5.7 EPS for the current year.

Genprex Profile

Genprex, Inc, a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes.